問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Digestive System Department

Division of General Internal Medicine

Division of General Surgery

Far Eastern Memorial Hospital (非在職)

Division of Hematology & Oncology

更新時間：2025-02-26

葉坤輝Yeh, Kun-Huei
  • Principal Investigator
  • Clinical Trial Experience (year) 24 years

Recruiting Trial

91Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

葉坤輝

List

194Cases

2013-07-30 - 2015-11-30

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2015-04-19 - 2019-12-31

Others

A Phase Ib/II, open-label, multicenter study of oral HDM201 in combination with oral LEE011 in adult patients with liposarcoma

  • Condition/Disease

    liposarcoma

  • Test Drug

    HDM201/Ribociclib (LEE011)

Participate Sites
1Sites

Terminated1Sites

2014-08-21 - 2016-12-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2012-05-15 - 2020-09-08

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2009-06-01 - 2012-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-06-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2019-04-01 - 2020-01-02

Others

A Phase Ib, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas

  • Condition/Disease

    Advanced/Metastatic Solid Tumors or Lymphomas

  • Test Drug

    MIW815 (ADU-S100) , PRD001

Participate Sites
1Sites

Terminated1Sites

2016-08-31 - 2018-12-31

Phase III

A Randomized, Open-label, Japan-Korea-Taiwan Collaborative Phase 3 Study to Compare the Efficacy of Nimotuzumab and Irinotecan Combination Therapy versus Irinotecan Monotherapy as Second Line Treatment in Subjects with Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer

  • Condition/Disease

    Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer

  • Test Drug

    DE-766 injection 50 mg/10mL vial

Participate Sites
11Sites

Terminated10Sites

趙毅
Taipei Veterans General Hospital

2012-05-23 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2006-02-01 - 2007-04-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

1 16 17 18 19 20
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB